Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ruiting, Chen, Ruilian, Chen, Zhiqiang, Hu, Leihao, Guo, Wei, Zhang, Zexin, Lin, Lizhu, Chen, Hanrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445031/
https://www.ncbi.nlm.nih.gov/pubmed/34540698
http://dx.doi.org/10.3389/fonc.2021.731572
_version_ 1784568573145907200
author Lin, Ruiting
Chen, Ruilian
Chen, Zhiqiang
Hu, Leihao
Guo, Wei
Zhang, Zexin
Lin, Lizhu
Chen, Hanrui
author_facet Lin, Ruiting
Chen, Ruilian
Chen, Zhiqiang
Hu, Leihao
Guo, Wei
Zhang, Zexin
Lin, Lizhu
Chen, Hanrui
author_sort Lin, Ruiting
collection PubMed
description The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations. Here, we report the case of a 68-year-old man with advanced NSCLC with concurrent EGFR L861Q mutation as well as TP53 and RB1 mutations. The patient was treated with osimertinib as first-line therapy and achieved a remarkable progression-free survival of 15 months. His symptoms were significantly alleviated and the dose was well tolerated. The findings of the present study indicate that osimertinib might be a good treatment option for NSCLC patients with the L861Q mutation.
format Online
Article
Text
id pubmed-8445031
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84450312021-09-17 Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review Lin, Ruiting Chen, Ruilian Chen, Zhiqiang Hu, Leihao Guo, Wei Zhang, Zexin Lin, Lizhu Chen, Hanrui Front Oncol Oncology The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations. Here, we report the case of a 68-year-old man with advanced NSCLC with concurrent EGFR L861Q mutation as well as TP53 and RB1 mutations. The patient was treated with osimertinib as first-line therapy and achieved a remarkable progression-free survival of 15 months. His symptoms were significantly alleviated and the dose was well tolerated. The findings of the present study indicate that osimertinib might be a good treatment option for NSCLC patients with the L861Q mutation. Frontiers Media S.A. 2021-09-02 /pmc/articles/PMC8445031/ /pubmed/34540698 http://dx.doi.org/10.3389/fonc.2021.731572 Text en Copyright © 2021 Lin, Chen, Chen, Hu, Guo, Zhang, Lin and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lin, Ruiting
Chen, Ruilian
Chen, Zhiqiang
Hu, Leihao
Guo, Wei
Zhang, Zexin
Lin, Lizhu
Chen, Hanrui
Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title_full Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title_fullStr Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title_full_unstemmed Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title_short Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
title_sort efficacy of osimertinib in nsclc harboring uncommon egfr l861q and concurrent mutations: case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445031/
https://www.ncbi.nlm.nih.gov/pubmed/34540698
http://dx.doi.org/10.3389/fonc.2021.731572
work_keys_str_mv AT linruiting efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT chenruilian efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT chenzhiqiang efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT huleihao efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT guowei efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT zhangzexin efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT linlizhu efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview
AT chenhanrui efficacyofosimertinibinnsclcharboringuncommonegfrl861qandconcurrentmutationscasereportandliteraturereview

Ejemplares similares